-
Product Insights
NewNet Present Value Model: Mustang Bio Inc’s MB-107
Empower your strategies with our Net Present Value Model: Mustang Bio Inc's MB-107 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
GSEC Mustang Gas Turbine Power Plant
GSEC Mustang Gas Turbine Power Plant is a thermal project located in Texas, United States. The project is owned by Golden Spread Electric Coop Inc. The project came online in 2006. Empower your strategies with our GSEC Mustang Gas Turbine Power Plant report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain...
-
Product Insights
NewNet Present Value Model: Calliditas Therapeutics AB’s Setanaxib
Empower your strategies with our Net Present Value Model: Calliditas Therapeutics AB's Setanaxib report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MB-103 in Brain Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MB-103 in Brain Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MB-103 in Brain Cancer Drug Details: MB-103 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BAT-6026 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BAT-6026 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BAT-6026 in Solid Tumor Drug Details: BAT-6026 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MB-207 in X-Linked SCID
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MB-207 in X-Linked SCID report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MB-207 in X-Linked SCID Drug Details: MB-207 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MB-103 in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MB-103 in Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MB-103 in Glioblastoma Multiforme (GBM) Drug Details: MB-103 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Talazoparib in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Talazoparib in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Talazoparib in Metastatic Breast Cancer Drug Details: Talazoparib (Talzenna, Tarzena) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MB-105 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MB-105 in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MB-105 in Pancreatic Cancer Drug Details: MB-105 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MB-106 in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MB-106 in Mantle Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MB-106 in Mantle Cell Lymphoma Drug Details: MB-106 is under investigation...